Search Tag: alirocumab

Cardiology Management

ODYSSEY Outcomes Trial: Does Reduction of Lipoprotein Reduce Cardiovascular Risk?

2020 27 Jan

Lipoprotein is believed to possess pro-atherogenic, pro-thrombotic, pro-inflammatory, and pro-oxidative properties. High levels of lipoprotein have been associated with incident cardiovascular disease in population-based epidemiological analysis and in patients with coronary heart disease (CHD). There is also a linear relationship between lipoprotein... Read more

Cardiology Management

Low utilisation of new cholesterol drugs

2017 03 Oct

Cholesterol lowering medications PCSK9 inhibitors (PCSK9i), alirocumab and evolocumab, were approved in 2015. Their high cost however has led to strict prior authorisation practices and high copays, curtailing use of PSCK9i in clinical practice, according to a new study published by JAMA Cardiology. PCSK9 inhibitors are typically prescribed by doctors... Read more